ThyroSafe 130mg Review: The New Full-Strength FDA Option
FDA VerifiedIn late 2025, ThyroSafe expanded its FDA-approved potassium iodide lineup with a 130mg full-strength variant (ASIN B0FPG5TSJP). This product addresses the primary criticism of the original ThyroSafe 65mg: that adults needed to take two tablets per dose. Now, a single ThyroSafe 130mg tablet delivers the complete adult dose.
Available in a 240-tablet package with expiration dates extending to April 2035, the ThyroSafe 130mg represents an attractive option for families and large households that want the ThyroSafe quality standard with the convenience of a one-tablet adult dose. It is distributed through MIRA Safety and available on Amazon with Transparency verification.
| Manufacturer | Recipharm AB (Sweden) |
|---|---|
| FDA Status | ANDA-Approved |
| Strength | 130mg per tablet |
| Count | 240 tablets |
| ASIN | B0FPG5TSJP |
| Expiration | April 2035 |
| Price | Varies |
Why Choose ThyroSafe 130mg Over iOSAT?
Both are FDA-approved 130mg tablets. The ThyroSafe 130mg comes in a 240-tablet bulk package — ideal for large families, community organizations, or anyone who wants an extended supply. iOSAT comes in 14-tablet individual foil packs with a 10-year shelf life. The choice depends on whether you prioritize bulk quantity (ThyroSafe 130mg) or individual packaging and maximum shelf life (iOSAT).
Who This Is For
Large families, community preparedness groups, employers with safety obligations, and anyone wanting a bulk supply of FDA-approved 130mg potassium iodide at a competitive per-tablet price. If you also need 65mg tablets for children, pair this with the original ThyroSafe 65mg.